¿Tienes alguna pregunta?
Email

LycellVax®

Lycellvax

LycellVax®
CELL-BASED IMMUNOTHERAPY

LycellVax™ is an immunotherapy that uses a bank of immunogenic tumour lysates to treat different types of cancer..

Although it shares scientific principles with TAPCells™, its main advantage is that production and inoculation are standardised and do not require blood to be obtained from the patient, making it highly versatile. 

LycellVax™ therapy was developed by a team led by Dr. Flavio Salazar at the Anti-Tumour Immunology Laboratory (ATIL) of the Faculty of Medicine at the University of Chile. Oncobiomed has the exclusive licence to manufacture and market LycellVax™

Results
Preclinical

Induces prophylactic and therapeutic protection against solid tumours of melanoma and colon cancer.

Effectiveness

Preliminary successful results completed in 2024.

Versatility and Safety

Standardised production and inoculation. No adverse side effects reported.

Contact

Contact

Address
Málaga 85, Las Condes
Santiago, Chile
Phone

+56 9 7753 2325

Email

Please include your phone number or WhatsApp in the message.